Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study.

Hangai S, Iwase S, Kawaguchi T, Kogure Y, Miyaji T, Matsunaga T, Nagumo Y, Yamaguchi T.

J Altern Complement Med. 2013 Nov;19(11):905-10. doi: 10.1089/acm.2012.0914. Epub 2013 Jul 5.

2.

Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.

Yorulmaz A, Dogan M, Artuz F, Zengin N.

Cutan Ocul Toxicol. 2017 Jun;36(2):135-139. doi: 10.3109/15569527.2016.1173698. Epub 2016 May 10.

PMID:
27086693
3.

TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.

Eckhoff L, Nielsen M, Moeller S, Knoop A.

Acta Oncol. 2011 Oct;50(7):1075-82. doi: 10.3109/0284186X.2011.602111. Epub 2011 Aug 9.

PMID:
21824038
4.

Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M.

Nutr Cancer. 2016;68(2):234-40. doi: 10.1080/01635581.2016.1134597. Epub 2016 Feb 4.

PMID:
26847832
5.

Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.

Shao N, Wang S, Yao C, Xu X, Zhang Y, Zhang Y, Lin Y.

Breast. 2012 Jun;21(3):389-93. doi: 10.1016/j.breast.2012.03.011. Epub 2012 Apr 26.

PMID:
22542064
6.

Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.

Davis AL, Klitus M, Mintzer DM.

Clin Breast Cancer. 2005 Dec;6(5):421-4.

PMID:
16381625
7.

Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C.

J Clin Oncol. 2007 Jan 20;25(3):292-300. Epub 2006 Dec 11.

PMID:
17159192
8.

The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.

Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI.

Toxicol Appl Pharmacol. 2007 Jul 15;222(2):152-8. Epub 2007 Apr 20.

PMID:
17555784
9.

Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy--the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy.

Ito T, Urushima H, Sakaue M, Yukawa S, Honda H, Hirai K, Igura T, Hayashi N, Maeda K, Kitagawa T, Kondo K.

Nutr Cancer. 2014;66(3):377-82. doi: 10.1080/01635581.2014.884232. Epub 2014 Mar 10.

PMID:
24611562
10.

Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.

Enright K, Grunfeld E, Yun L, Moineddin R, Ghannam M, Dent S, Eisen A, Trudeau M, Kaizer L, Earle C, Krzyzanowska MK.

J Oncol Pract. 2015 Mar;11(2):126-32. doi: 10.1200/JOP.2014.001073. Epub 2015 Jan 20.

PMID:
25604597
11.

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.

Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R, Capasso I, Casaretti R, Daponte A, Caponigro F, Gravina A, Maiorino L, CaratenĂ­ G, Gentile A, Comella G.

Breast Cancer Res Treat. 1998 May;49(1):13-26.

PMID:
9694607
12.

Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer.

Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH 4th.

Am J Surg. 2013 Apr;205(4):397-401. doi: 10.1016/j.amjsurg.2013.01.009. Epub 2013 Feb 16.

PMID:
23422317
13.

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.

Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH; ANC Study Group.

Breast Cancer Res Treat. 2006 Dec;100(3):255-62. Epub 2006 May 17.

PMID:
16705366
14.

Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?

Davidson A, Gelmon K.

Future Oncol. 2011 Jan;7(1):37-55. doi: 10.2217/fon.10.163. Review.

PMID:
21174537
15.

Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice.

Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H.

J Exp Ther Oncol. 2009;8(1):43-51.

PMID:
19827270
16.

Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.

Sukel MP, Breekveldt-Postma NS, Erkens JA, van der Linden PD, Beiderbeck AB, Coebergh JW, Herings RM.

Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):125-34.

PMID:
18058835
18.

Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.

Weycker D, Edelsberg J, Kartashov A, Barron R, Lyman G.

Chemotherapy. 2012;58(1):8-18. doi: 10.1159/000335604. Epub 2012 Feb 14.

19.

Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy.

Bourdeanu L, Frankel P, Yu W, Hendrix G, Pal S, Badr L, Somlo G, Luu T.

J Support Oncol. 2012 Jul-Aug;10(4):149-54. doi: 10.1016/j.suponc.2011.10.007. Epub 2012 Jan 4.

PMID:
22222249
20.

[Use of Taxotere in adjuvant chemotherapy of breast cancer].

Besova NS.

Vopr Onkol. 2011;57(5):651-7. Russian. No abstract available.

PMID:
22238938

Supplemental Content

Support Center